• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

byKassandra McFarlaneandSamuel Chan
March 28, 2022
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine

2. Adverse events were more common in patients taking trastuzumab deruxtecan than those taking trastuzumab emtansine

Evidence Rating Level: 1 (Excellent)

Study Rundown: This study aimed to compare the progression-free survival (PFS) of women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer receiving either trastuzumab emtansine (TE), the standard treatment, or trastuzumab deruxtecan (TD), a HER2 antibody-drug conjugate. Secondary outcomes included the safety profile as measured by adverse events (AEs). The PFS was 6.8 months in the TE group and unobtainable in the TD group. There were 34.1% of patients still alive in the TE group at 1 year, compared to 75.8% in the TD group, according to blinded central review. Nausea was the most commonly reported drug-related AE of any severity, followed by fatigue and vomiting. These AEs were higher in the TD group than the TE group. Neutropenia, thrombocytopenia, and leukopenia were the most common severe drug-related AEs. Neutropenia and leukopenia were higher in the TD than the TE group, while thrombocytopenia was higher in the TE than the TD group. Interstitial lung disease or pneumonitis was more common in the TD group than in the TE group and accounted for 8.2% and 1.1% of treatment discontinuations respectively. Generally, discontinuation due to AEs was more common in the TD group compared to the TE group. Limitations to this study include that some measures were not obtained by the study cutoff date, including median overall survival. Overall, trastuzumab deruxtecan appears to reduce the risk of disease progression as compared to trastuzumab emtansine.

Click to read the study in The New England Journal of Medicine

Relevant Reading: Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

In-Depth [randomized controlled trial]: This multi-national, phase 3, open-label, randomized controlled trial randomly assigned 524 female patients with HER2-positive metastatic breast cancer on a 1:1 basis to receive either trastuzumab emtansine (TE) or trastuzumab deruxtecan (TD). There were 263 in the TE group and 261 in the TD group. The medications were provided by intravenous route every 3 weeks. The median PFS was 6.8 months in the TE group (95% confidence interval (CI)), while it was unobtainable in the TD group (95% CI, 18.5 months to ‘could not be estimated’). According to blinded central review, the percent of patients alive at 1 year without disease progression was 34.1% in the TE group (95% CI, 27.7% to 40.5%) compared to 75.8% (95% CI, 69.8% to 80.7%) in the TD group (hazard ratio (HR) 0.28; 95% CI, 0.22 to 0.37). Nausea, fatigue, and vomiting were the most common drug-related AEs, and were higher in the TD group than the TE group. Severe drug-related AEs included neutropenia, thrombocytopenia, and leukopenia. Neutropenia and leukopenia were higher in the TD than in the TE group (19.1% vs 3.1%, 6.6% vs 0.4%), while thrombocytopenia was higher in the TE than in the TD group (24.9% vs 7.0%). Interstitial lung disease or pneumonitis was more common in the TD group than in the TE group (10.5% vs 1.9%) and resulted in treatment discontinuation in 8.2% and 1.1% of each group, respectively. Serious AEs presented in 18.0% of TE patients, and 19.1% of TD patients. Discontinuation due to AEs was more common in the TD group (13.6%) compared to the TE group (7.3%).

RELATED REPORTS

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced breast cancerHer2trastuzumab deruxtecan
Previous Post

Darolutamide with chemotherapy and androgen-deprivation therapy improves overall survival in metastatic hormone-sensitive prostate cancer

Next Post

Hydrocortisone does not improve bronchopulmonary dysplasia outcomes in pre-term babies

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

March 29, 2022
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Oncology

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

March 21, 2022
Endocrinology

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

March 17, 2022
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
StudyGraphics

#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer

February 15, 2022
Next Post
Poverty, preterm birth demonstrate additive effect on cognition

Hydrocortisone does not improve bronchopulmonary dysplasia outcomes in pre-term babies

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

Higher religious adherence may be associated with lower mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.